Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM5TVS3)

Drug Name
Vinblastine Drug Info
Synonyms
Nincaluicolflastine; Rozevin; VLB; Vinblastin; Vinblastina; Vinblastinum; Vincaleucoblastin; Vincaleucoblastine; Vincaleukoblastine; Vincoblastine; Vinblastina [DCIT]; VR-8; Vinblastina (TN); Vinblastine (INN); Vinblastine [INN:BAN]; Vinblastinum [INN-Latin]; NDC 0002-1452-01; (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
13342
ChEBI ID
CHEMBL159
CAS Number
CAS 865-21-4
TTD Drug ID
D0W9MM
VARIDT Drug ID
DR00308
INTEDE Drug ID
DR1689

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Salmonella infection 2.09 0.00e+0 198/249 (79.52%) PODXL;TUBB2A;FLNA;...
Focal adhesion 2.08 0.00e+0 180/201 (89.55%) ITGA6;ACTN1;CAV1;...
Renal cell carcinoma 1.83 4.14e-2 68/69 (98.55%) TGFA;JUN;ETS1;...
Bacterial invasion of epithelial cells 1.82 3.55e-2 59/77 (76.62%) CAV1;CAV2;ILK;...
Shigellosis 1.81 2.96e-2 180/246 (73.17%) ACTN1;CAPN2;ILK;...
Hypertrophic cardiomyopathy 1.81 2.53e-2 81/90 (90%) ITGA6;TPM1;TPM4;...
Regulation of actin cytoskeleton 1.80 2.22e-2 185/218 (84.86%) ITGA6;ACTN1;ITGA5;...
Proteoglycans in cancer 1.80 2.23e-2 172/205 (83.9%) CAV1;CAV2;ITGA5;...
NF-kappa B signaling pathway 1.80 2.01e-2 90/104 (86.54%) IRAK1;RELB;CXCL3;...
Tight junction 1.79 2.04e-2 130/169 (76.92%) ACTN1;ACTN4;PPP2CB;...
Dilated cardiomyopathy 1.76 2.27e-2 86/96 (89.58%) ITGA6;TPM1;TPM4;...
ECM-receptor interaction 1.76 2.18e-2 80/88 (90.91%) ITGA6;LAMC2;ITGA5;...
ErbB signaling pathway 1.75 2.28e-2 79/85 (92.94%) EREG;AREG;HBEGF;...
MAPK signaling pathway 1.74 2.21e-2 272/294 (92.52%) EREG;AREG;EPHA2;...
Bladder cancer 1.72 2.66e-2 40/41 (97.56%) HBEGF;THBS1;CXCL8;...
PI3K-Akt signaling pathway 1.69 3.13e-2 317/354 (89.55%) ITGA6;EREG;AREG;...
Arrhythmogenic right ventricular cardiomyopathy 1.68 3.09e-2 70/77 (90.91%) ITGA6;ITGA5;ITGA3;...
Ras signaling pathway 1.68 3.11e-2 201/232 (86.64%) EPHA2;PDGFC;TGFA;...
Small cell lung cancer 1.67 3.07e-2 90/92 (97.83%) ITGA6;LAMC2;ITGA3;...
Pathogenic Escherichia coli infection 1.67 2.98e-2 152/197 (77.16%) TUBB2A;IRAK1;JUN;...
Leukocyte transendothelial migration 1.67 2.85e-2 90/114 (78.95%) ACTN1;ACTN4;MSN;...
Hematopoietic cell lineage 1.66 2.93e-2 90/99 (90.91%) ITGA6;ITGA5;IL7R;...
Amoebiasis 1.61 4.97e-2 99/102 (97.06%) ACTN1;LAMC2;ACTN4;...
Alanine, aspartate and glutamate metabolism -1.56 4.59e-2 27/37 (72.97%) ABAT;GAD2;GLUD1;...
Base excision repair -1.56 4.61e-2 29/33 (87.88%) POLB;NTHL1;APEX2;...
Propanoate metabolism -1.57 4.42e-2 30/34 (88.24%) ACSS3;SUCLA2;BCKDHB;...
Vitamin digestion and absorption -1.58 4.44e-2 17/24 (70.83%) BTD;SLC5A6;APOB;...
Porphyrin and chlorophyll metabolism -1.58 4.58e-2 23/43 (53.49%) HEPH;ALAD;UGT2B4;...
Glutathione metabolism -1.62 2.99e-2 43/57 (75.44%) G6PD;GSTK1;GGCT;...
Fructose and mannose metabolism -1.63 3.08e-2 30/33 (90.91%) PFKL;HK2;TKFC;...
Retinol metabolism -1.63 3.15e-2 41/68 (60.29%) ADH7;CYP26B1;UGT2B4;...
Peroxisome -1.70 1.72e-2 72/82 (87.8%) PEX7;GSTK1;SOD2;...
Tyrosine metabolism -1.71 1.42e-2 30/36 (83.33%) HGD;DCT;ADH1B;...
Fanconi anemia pathway -1.72 1.49e-2 36/54 (66.67%) ATR;BLM;RAD51;...
Proximal tubule bicarbonate reclamation -1.73 1.31e-2 21/23 (91.3%) ATP1A2;CA4;GLUD1;...
Bile secretion -1.80 6.70e-3 68/90 (75.56%) UGT2B4;ATP1A2;SLC27A5;...
Primary bile acid biosynthesis -1.82 6.62e-3 15/17 (88.24%) ACOX2;CYP7B1;ACOT8;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis -1.82 7.03e-3 20/26 (76.92%) PIGH;PIGA;MPPE1;...
Folate biosynthesis -1.88 3.22e-3 23/26 (88.46%) PAH;AKR1B1;DHFR;...
Arachidonic acid metabolism -1.90 2.30e-3 48/61 (78.69%) ALOX15;PTGES;PTGIS;...
Pyruvate metabolism -1.91 1.85e-3 41/47 (87.23%) LDHB;FH;ADH7;...
Glyoxylate and dicarboxylate metabolism -1.92 2.01e-3 23/30 (76.67%) MMUT;GLDC;ACO2;...
Nitrogen metabolism -1.95 1.46e-3 16/17 (94.12%) CA5A;CA4;GLUD1;...
Ascorbate and aldarate metabolism -2.03 0.00e+0 15/30 (50%) AKR1A1;UGT2B4;UGDH;...
Pentose and glucuronate interconversions -2.05 0.00e+0 17/34 (50%) AKR1A1;UGT2B4;UGDH;...
Fatty acid degradation -2.08 0.00e+0 40/43 (93.02%) ACADS;GCDH;ACSL6;...
Drug metabolism -2.09 0.00e+0 78/151 (51.66%) GSTK1;FMO1;DPYD;...
Glycolysis / Gluconeogenesis -2.14 0.00e+0 56/67 (83.58%) ADH7;AKR1A1;ADH1A;...
Mismatch repair -2.14 0.00e+0 22/23 (95.65%) RPA2;RFC2;RFC4;...
Steroid hormone biosynthesis -2.14 0.00e+0 43/61 (70.49%) CYP19A1;CYP3A7;CYP11B2;...
Histidine metabolism -2.26 0.00e+0 16/22 (72.73%) ALDH9A1;ASPA;ALDH3A2;...
Metabolism of xenobiotics by cytochrome P450 -2.36 0.00e+0 49/77 (63.64%) GSTK1;CYP1A2;GSTA3;...
DNA replication -2.46 0.00e+0 34/36 (94.44%) RPA2;RFC2;RFC4;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 2.5uM - 10uM 6H, 24H, 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H